These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Influence of physiochemical properties on the subcutaneous absorption and bioavailability of monoclonal antibodies. Datta-Mannan A; Estwick S; Zhou C; Choi H; Douglass NE; Witcher DR; Lu J; Beidler C; Millican R MAbs; 2020 Jan; 12(1):1770028. PubMed ID: 32486889 [TBL] [Abstract][Full Text] [Related]
6. Physicochemical Stability of Monoclonal Antibodies: A Review. Le Basle Y; Chennell P; Tokhadze N; Astier A; Sautou V J Pharm Sci; 2020 Jan; 109(1):169-190. PubMed ID: 31465737 [TBL] [Abstract][Full Text] [Related]
7. Subcutaneous delivery of monoclonal antibodies: How do we get there? Viola M; Sequeira J; Seiça R; Veiga F; Serra J; Santos AC; Ribeiro AJ J Control Release; 2018 Sep; 286():301-314. PubMed ID: 30077735 [TBL] [Abstract][Full Text] [Related]
8. Improving the outcomes of biopharmaceutical delivery via the subcutaneous route by understanding the chemical, physical and physiological properties of the subcutaneous injection site. Kinnunen HM; Mrsny RJ J Control Release; 2014 May; 182():22-32. PubMed ID: 24631859 [TBL] [Abstract][Full Text] [Related]
9. Formulating monoclonal antibodies as powders for reconstitution at high concentration using spray drying: Models and pitfalls. Batens M; Massant J; Teodorescu B; Van den Mooter G Eur J Pharm Biopharm; 2018 Jun; 127():407-422. PubMed ID: 29499299 [TBL] [Abstract][Full Text] [Related]
10. Understanding the Monoclonal Antibody Disposition after Subcutaneous Administration using a Minimal Physiologically based Pharmacokinetic Model. Varkhede N; Forrest ML J Pharm Pharm Sci; 2018; 21(1s):130s-148s. PubMed ID: 30011390 [TBL] [Abstract][Full Text] [Related]
11. A compartment model for subcutaneous injection of monoclonal antibodies. Zhong X; Liu Y; Ardekani AM Int J Pharm; 2024 Jan; 650():123687. PubMed ID: 38103705 [TBL] [Abstract][Full Text] [Related]
12. Hydrogen-deuterium exchange mass spectrometry as an emerging analytical tool for stabilization and formulation development of therapeutic monoclonal antibodies. Majumdar R; Middaugh CR; Weis DD; Volkin DB J Pharm Sci; 2015 Feb; 104(2):327-45. PubMed ID: 25354868 [TBL] [Abstract][Full Text] [Related]
13. In Vivo Stability of Therapeutic Proteins. Schuster J; Koulov A; Mahler HC; Detampel P; Huwyler J; Singh S; Mathaes R Pharm Res; 2020 Jan; 37(2):23. PubMed ID: 31900680 [TBL] [Abstract][Full Text] [Related]
14. Application of Affinity-Capture Self-Interaction Nanoparticle Spectroscopy in Predicting Protein Stability, Especially for Co-Formulated Antibodies. Zhou M; Yan Z; Li H; Liu X; Sun P Pharm Res; 2021 Apr; 38(4):721-732. PubMed ID: 33754257 [TBL] [Abstract][Full Text] [Related]
15. The use of intravenous versus subcutaneous monoclonal antibodies in the treatment of severe asthma: a review. Matucci A; Vultaggio A; Danesi R Respir Res; 2018 Aug; 19(1):154. PubMed ID: 30115042 [TBL] [Abstract][Full Text] [Related]
16. How spray drying processing and solution composition can affect the mAbs stability in reconstituted solutions for subcutaneous injections. Part II: Exploring each protein stabilizer effect. Barcelo-Chong CM; Filipe V; Nakach M; Inês Ré M Int J Pharm; 2024 Apr; 655():124014. PubMed ID: 38513817 [TBL] [Abstract][Full Text] [Related]
17. How spray drying processing and solution composition can affect the mAbs stability in reconstituted solutions for subcutaneous injections. Part I: Contribution of processing stresses against composition. Barceló-Chong CM; Filipe V; Nakach M; Ré MI Int J Pharm; 2024 Apr; 655():123925. PubMed ID: 38518870 [TBL] [Abstract][Full Text] [Related]